Shawver Laura 4
4 · ARS Pharmaceuticals, Inc. · Filed Jan 7, 2025
Insider Transaction Report
Form 4
Shawver Laura
Director
Transactions
- Exercise/Conversion
Common Stock
2025-01-06$3.15/sh+50,000$157,500→ 260,346 total - Sale
Common Stock
2025-01-06$11.10/sh−50,000$555,065→ 210,346 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-01-06−50,000→ 9,064 totalExercise: $3.15Exp: 2032-05-01→ Common Stock (50,000 underlying)
Footnotes (3)
- [F1]The shares reported on this Form 4 were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 16, 2024.
- [F2]The weighted average sale price for the transaction reported was $11.1013 and the range of prices were between $11.00 and $11.43. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
- [F3]Immediately exercisable.